Kimera Labs, a specialty contract research organization (CRO), has announced the launch of a 6,000 sq ft, ISO:9001 certified exosome production facility in Miramar, Florida. As an FDA registered tissue facility, Kimera Labs Miramar will produce tissue specific mesenchymal stem cell (MSC) derived exosomes, as well as its Amnio2x amniotic fluid derived products. Amnio2x can be used for orthopedic, cosmetic and regenerative medicine applications.
Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells. Exosomes are commonly found in blood, urine, saliva, synovial fluid, amniotic fluid, semen, and many other fluids.
It has become recognized within the research community that exosomes play a central role in facilitating the regenerative functions of mesenchymal stem cells (MSCs), as well as other stem cell types.
“In many cell-based therapeutic applications, long distance paracrine signaling via microvesicles is emerging as the primary mode of action for tissue regeneration,” said Duncan Ross Ph.D., President of Kimera Labs. “With over 300 growth factors and thousands of nucleic acids, the KM300 series of exosomes is a frozen, off the shelf solution to inflammatory disease and tissue dysfunction. With the clear functionality of our topical XoGlo product for skin quality enhancement and recovery after cosmetic procedures, it is clear that seeing is believing when exosomes are employed in the clinic.”
Interested to learn ore? View “The Market for Stem Cell Exosomes.”
